周光飚，1969年生，籍贯广西壮族自治区，肿瘤生物学家，肿瘤医院研究员，博士生导师。1988年考入广西医科大学临床医学专业，1993年获得学士学位。1997年在中南大学湘雅医学院内科学专业攻读硕士学位，从事血液学研究。2000年在上海交通大学医学院内科学专业攻读博士学位，从事血液学研究。2003年进入中国科学院上海生命科学研究院进行博士后研究工作，主要研究白血病。2005年升为副研究员。

研究方向一为肺癌发生机理，发现驱动肺癌的关键基因、尘搁狈础异常剪接、炎症因子、抑制性免疫微环境及代谢小分子；研究方向二为中药抗肿瘤药理，研究抗癌中药的作用机理，并探索肿瘤免疫治疗的增效策略及抗肺癌复方。

天美麻花星空

1.Liang F, Wang GZ, Wang Y, Yang YN, Wen ZS, Chen DN, Fang WF, Zhang B, Yang L, Zhang C, Han SC, Yang FY, Wang D, Liang LJ, Wang Z, Zhao Y, Wang CL, Zhang L, Zhou GB*. Tobacco carcinogen induces tryptophan metabolism and immune suppression via induction of indoleamine 2,3-dioxygenase 1. Signal Transduct Target Ther. 2022 ,7(1):311. (IF=38.104)

2. Zhang C, Zhang J, Liang F, Guo H, Gao S, Yang F, Guo H, Wang G, Wang W*, Zhou G*. Innate immune checkpoint Siglec10 in cancers: mining of comprehensive omics data and validation in patient samples. Front Med, 2022; doi: 10.1007/s11684-021-0868-z.Online ahead of print (IF=9.927).

3. Chen JM, Zhu WJ, Liu J, Wang GZ, Chen XQ, Tan Y, Xu WW, Qu LW, Li JY, Yang HJ, Huang L, Cai N, Wang WD, Huang K, Xu JQ, Li GH, He S, Luo TY, Huang Y, Liu SH, Wu WQ, Lu QY, Zhou MG, Chen SY, Li RL, Hu ML, Huang Y, Wei JH, Li JM, Chen SJ*, Zhou GB*. Safety and efficacy of thalidomide in patients with transfusion-dependent β-thalassemia: a randomized clinical trial. Signal Transduct Target Ther. 2021;6:405. (IF=18.187)

4. Zhao Q, Guo J, Wang G, Bi Y, Cheng X, Liao Y, Jin S, Li L, Guo Y, Pan L, Zhang X, Tan Y, Zhou G*, Yu X*. CXCL13 promotes intestinal tumorigenesis through the activation of epithelial AKT signaling. Cancer Lett. 2021; 511: 1-14. (IF=8.697)

5. Wang GZ, Zhang L, Zhao XC, Gao SH, Qu LW, Yu H, Fang WF, Zhou YC, Liang F, Zhang C, Huang YC, Liu Z, Fu YX, Zhou GB*. The Aryl hydrocarbon receptor mediates tobacco-induced PD-L1 expression and is associated with response to immunotherapy. Nat Commun, 2019; 10: 1125. (IF=11.878; Biocentury推荐)

6. Zhou B, Wang GZ, Wen ZS, Zhou YC, Huang YC, Chen Y, Zhou GB*. Somatic mutations and splicing variants of focal adhesion kinase in non-small cell lung cancer. J Natl Cancer Inst, 2018; 110: 195-204. (IF=11.238)

7. Wang GZ, Cheng X, Zhou B, Wen ZS, Huang YC, Chen HB, Li GF, Huang ZL, Zhou YC, Feng L, Wei MM, Qu LW, Cao Y, Zhou GB*. The chemokine CXCL13 in lung cancers associated with environmental polycyclic aromatic hydrocarbons pollution. Elife, 2015; 4: e09419. (IF=9.322)

8. Yu XJ, Yang MJ, Zhou B, Wang GZ, Huang YC, Wu LC, Cheng X, Wen ZS, Huang JY, Zhang YD, Gao XH, Li GF, He SW, Gu ZH, Ma L, Pan CM, Wang P, Chen HB, Hong ZP, Wang XL, Mao WJ, Jin XL, Kang H, Chen ST, Zhu YQ, Gu WY, Liu Z, Dong H, Tian LW, Chen SJ*, Cao Y*, Wang SY*, Zhou GB*. Characterization of somatic mutations in air pollution-related lung cancer. EBioMedicine, 2015; 2:583-590. (F1000)

9. Fang HT, Zhang B, Pan XF, Gao L, Zhen T, Zhao HX, Ma L, Xie J, Liu Z, Yu XJ, Cheng X, Feng TT, Zhang FX, Yang Y, Hu ZG, Sheng GQ, Chen YL, Chen SJ*, Chen Z*, Zhou GB*. Bortezomib interferes with C-KIT processing and transforms the t(8;21)-generated fusion proteins into tumor-suppressing fragments in leukemia cells. Proc Natl Acad Sci U S A, 2012;109: 2521-2526.(IF=9.737)

10. Zhou GB#*, Kang H#, Wang L#, Gao L#, Liu P, Xie J, Zhang FX, Weng XQ, Shen ZX, Chen J, Gu LJ, Yan M, Zhang DE, Chen SJ, Wang ZY, Chen Z*. Oridonin, a diterpenoid extracted from medicinal herbs, targets AML1-ETO fusion protein and shows potent antitumor activity with low adverse effects on t(8;21) leukemia in vitro and in vivo. Blood, 2007; 109:3441-3450.(IF=10.896; C100)